{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:17:48Z","timestamp":1792649868713,"version":"4.5.0"},"reference-count":186,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.pharmthera.2020.107527","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T13:57:19Z","timestamp":1584021439000},"page":"107527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"special_numbering":"C","title":["Evaluating the benefits of renin-angiotensin system inhibitors as cancer treatments"],"prefix":"10.1016","volume":"211","author":[{"given":"Marcos V.","family":"Perini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhynelle S.","family":"Dmello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy L.","family":"Nero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwini L.","family":"Chand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2020.107527_bb0010","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/carcin\/bgn171","article-title":"The renin-angiotensin system and malignancy","volume":"29","author":"Ager","year":"2008","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0015","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jmb.2010.05.024","article-title":"High-resolution crystal structures of Drosophila melanogaster angiotensin-converting enzyme in complex with novel inhibitors and antihypertensive drugs","volume":"400","author":"Akif","year":"2010","journal-title":"Journal of Molecular Biology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0020","doi-asserted-by":"crossref","first-page":"23382","DOI":"10.1074\/jbc.272.37.23382","article-title":"Dependence on the motif YIPP for the physical association of Jak2 kinase with the intracellular carboxyl tail of the angiotensin II AT1 receptor","volume":"272","author":"Ali","year":"1997","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0025","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.coph.2010.12.003","article-title":"Role of angiotensin in the rostral ventrolateral medulla in the development and maintenance of hypertension","volume":"11","author":"Allen","year":"2011","journal-title":"Current Opinion in Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0030","doi-asserted-by":"crossref","first-page":"31S","DOI":"10.1016\/S0895-7061(99)00249-6","article-title":"Localization and function of angiotensin AT1 receptors","volume":"13","author":"Allen","year":"2000","journal-title":"American Journal of Hypertension"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0035","first-page":"849","article-title":"Angiotensin II activates MAP kinase and NF-kappaB through angiotensin II type I receptor in human pancreatic cancer cells","volume":"25","author":"Amaya","year":"2004","journal-title":"International Journal of Oncology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0040","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11605-007-0403-9","article-title":"Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1\/2 signaling","volume":"12","author":"Anandanadesan","year":"2008","journal-title":"Journal of Gastrointestinal Surgery"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0045","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1021\/jm00381a021","article-title":"Conformational analysis and active site modelling of angiotensin-converting enzyme inhibitors","volume":"28","author":"Andrews","year":"1985","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0050","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jamcollsurg.2007.01.067","article-title":"Antihypertensives as novel antineoplastics: Angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma","volume":"204","author":"Arafat","year":"2007","journal-title":"Journal of the American College of Surgeons"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0055","doi-asserted-by":"crossref","first-page":"e31384","DOI":"10.1371\/journal.pone.0031384","article-title":"Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFbeta activation","volume":"7","author":"Arnold","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0060","doi-asserted-by":"crossref","first-page":"R71","DOI":"10.1530\/JME-14-0125","article-title":"Structural determinants for binding, activation, and functional selectivity of the angiotensin AT1 receptor","volume":"53","author":"Balakumar","year":"2014","journal-title":"Journal of Molecular Endocrinology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0065","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(10)70260-6","article-title":"Antihypertensive drugs and risk of cancer: Network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials","volume":"12","author":"Bangalore","year":"2011","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0070","first-page":"PE16","article-title":"Angiotensin type 2 receptor (AT2R): A challenging twin","volume":"2003","author":"Berk","year":"2003","journal-title":"Science\u2019s STKE"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.112.006809","article-title":"A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme","volume":"65","author":"Bernstein","year":"2013","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0080","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1189\/jlb.0310153","article-title":"NF-kappaB as a central regulator of macrophage function in tumors","volume":"88","author":"Biswas","year":"2010","journal-title":"Journal of Leukocyte Biology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0085","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/ni.1937","article-title":"Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm","volume":"11","author":"Biswas","year":"2010","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0090","first-page":"51","article-title":"Glioblastoma multiforme cancer stem cells express components of the renin-angiotensin system","volume":"3","author":"Bradshaw","year":"2016","journal-title":"Front Surg"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0095","doi-asserted-by":"crossref","first-page":"e1800102","DOI":"10.1002\/prca.201800102","article-title":"Proteomic approach to the potential role of angiotensin II in Barrett dysplasia","volume":"13","author":"Bratlie","year":"2019","journal-title":"Proteomics. Clinical Applications"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0100","doi-asserted-by":"crossref","first-page":"F585","DOI":"10.1152\/ajprenal.00538.2009","article-title":"Angiotensin II mediates epithelial-to-mesenchymal transformation in tubular cells by ANG 1-7\/MAS-1-dependent pathways","volume":"299","author":"Burns","year":"2010","journal-title":"American Journal of Physiology. Renal Physiology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0105","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1021\/jm031100t","article-title":"Design, synthesis, structural studies, biological evaluation, and computational simulations of novel potent AT(1) angiotensin II receptor antagonists based on the 4-phenylquinoline structure","volume":"47","author":"Cappelli","year":"2004","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0110","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/0-306-47384-4_3","article-title":"The discovery and development of angiotensin II antagonists","volume":"11","author":"Carini","year":"1998","journal-title":"Pharmaceutical Biotechnology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0115","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1021\/jm00112a031","article-title":"Nonpeptide angiotensin II receptor antagonists: The discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensives","volume":"34","author":"Carini","year":"1991","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0120","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.bmcl.2012.11.088","article-title":"Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-gamma","volume":"23","author":"Casimiro-Garcia","year":"2013","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0125","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1245\/s10434-017-5812-8","article-title":"Tumor-associated macrophage infiltration in colorectal cancer liver metastases is associated with better outcome","volume":"24","author":"Cavnar","year":"2017","journal-title":"Annals of Surgical Oncology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2007.07.061","article-title":"Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE","volume":"577","author":"Ceconi","year":"2007","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0135","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3109\/07357907.2011.616252","article-title":"Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and\/or statins","volume":"29","author":"Chae","year":"2011","journal-title":"Cancer Investigation"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0140","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.tibs.2018.11.011","article-title":"New binding sites, new opportunities for GPCR drug discovery","volume":"44","author":"Chan","year":"2019","journal-title":"Trends in Biochemical Sciences"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0145","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1016\/j.jacc.2017.09.1096","article-title":"Cardiovascular complications of cancer therapy: Best practices in diagnosis, prevention, and management: Part 1","volume":"70","author":"Chang","year":"2017","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0150","doi-asserted-by":"crossref","first-page":"10674","DOI":"10.1073\/pnas.1819889116","article-title":"Reprogramming the microenvironment with tumor-selective angiotensin blockers enhances cancer immunotherapy","volume":"116","author":"Chauhan","year":"2019","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0155","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1038\/ncomms3516","article-title":"Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels","volume":"4","author":"Chauhan","year":"2013","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0160","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.micron.2010.01.005","article-title":"Porcine pulmonary angiotensin I-converting enzyme--biochemical characterization and spatial arrangement of the N- and C-domains by three-dimensional electron microscopic reconstruction","volume":"41","author":"Chen","year":"2010","journal-title":"Micron"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0165","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/MCB.06410-11","article-title":"Angiotensin II induces epithelial-to-mesenchymal transition in renal epithelial cells through reactive oxygen species\/Src\/caveolin-mediated activation of an epidermal growth factor receptor-extracellular signal-regulated kinase signaling pathway","volume":"32","author":"Chen","year":"2012","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0170","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nature13905","article-title":"MicroRNA silencing for cancer therapy targeted to the tumour microenvironment","volume":"518","author":"Cheng","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0175","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/jch.12228","article-title":"Lowered cancer risk with ACE inhibitors\/ARBs: A population-based cohort study","volume":"16","author":"Chiang","year":"2014","journal-title":"Journal of Clinical Hypertension (Greenwich, Conn.)"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0180","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/HJH.0b013e328344a7de","article-title":"Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals","volume":"29","year":"2011","journal-title":"Journal of Hypertension"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0185","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1021\/bi700275e","article-title":"The structure of testis angiotensin-converting enzyme in complex with the C domain-specific inhibitor RXPA380","volume":"46","author":"Corradi","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0190","first-page":"6735","article-title":"Human gastric carcinogenesis: A multistep and multifactorial process--First American Cancer Society award lecture on cancer epidemiology and prevention","volume":"52","author":"Correa","year":"1992","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0195","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0140-6736(75)90498-5","article-title":"A model for gastric cancer epidemiology","volume":"2","author":"Correa","year":"1975","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0200","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.immuni.2012.10.015","article-title":"Angiotensin II drives the production of tumor-promoting macrophages","volume":"38","author":"Cortez-Retamozo","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0205","doi-asserted-by":"crossref","first-page":"18640","DOI":"10.18632\/oncotarget.15553","article-title":"The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma","volume":"8","author":"Coulson","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0210","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/febs.14421","article-title":"Crystal structures of sampatrilat and sampatrilat-Asp in complex with human ACE - a molecular basis for domain selectivity","volume":"285","author":"Cozier","year":"2018","journal-title":"The FEBS Journal"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0215","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1681\/ASN.2016101066","article-title":"Immunologic effects of the renin-angiotensin system","volume":"28","author":"Crowley","year":"2017","journal-title":"Journal of the Americal Society of Nephrology"},{"issue":"Suppl. 2","key":"10.1016\/j.pharmthera.2020.107527_bb0220","first-page":"115S","article-title":"Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE)","volume":"28","author":"Cushman","year":"1989","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0225","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/ncpcardio1375","article-title":"Vascular complications of selected cancer therapies","volume":"5","author":"Daher","year":"2008","journal-title":"Nature Clinical Practice. Cardiovascular Medicine"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0230","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0235","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s00280-011-1604-1","article-title":"Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients","volume":"68","author":"De Stefano","year":"2011","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0240","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ypmed.2017.01.011","article-title":"Relationship between drugs affecting the renin-angiotensin system and colorectal cancer: The MCC-Spain study","volume":"99","author":"Dierssen-Sotos","year":"2017","journal-title":"Preventive Medicine"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0245","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1073\/pnas.1018892108","article-title":"Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors","volume":"108","author":"Diop-Frimpong","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0250","doi-asserted-by":"crossref","DOI":"10.3390\/cancers8010008","article-title":"Cancer stem cell plasticity drives therapeutic resistance","volume":"8","author":"Doherty","year":"2016","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0255","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1471-2407-10-67","article-title":"Angiotensin II type 2 receptor signaling significantly attenuates growth of murine pancreatic carcinoma grafts in syngeneic mice","volume":"10","author":"Doi","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0260","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0022-3565(25)11212-3","article-title":"Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566","volume":"260","author":"Edwards","year":"1992","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0265","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1172\/JCI16645","article-title":"Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth","volume":"112","author":"Egami","year":"2003","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0270","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ijpharm.2016.10.013","article-title":"Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems","volume":"515","author":"van Elk","year":"2016","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0275","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1593\/tlo.13346","article-title":"Exposure to ACEI\/ARB and beta-blockers is associated with improved survival and decreased tumor progression and hospitalizations in patients with advanced colon cancer","volume":"6","author":"Engineer","year":"2013","journal-title":"Translational Oncology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0280","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jacc.2008.02.088","article-title":"Detection of soluble angiotensin-converting enzyme 2 in heart failure: Insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system","volume":"52","author":"Epelman","year":"2008","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0285","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.3389\/fphar.2018.01230","article-title":"Tumor microenvironment targeted nanotherapy","volume":"9","author":"Fernandes","year":"2018","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0290","doi-asserted-by":"crossref","first-page":"8187","DOI":"10.1074\/jbc.M112.442053","article-title":"Structure of the human angiotensin II type 1 (AT1) receptor bound to angiotensin II from multiple chemoselective photoprobe contacts reveals a unique peptide binding mode","volume":"288","author":"Fillion","year":"2013","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0295","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1002\/1097-0142(20011101)92:9<2462::AID-CNCR1596>3.0.CO;2-L","article-title":"Angiotensin-converting enzyme inhibitors and the risk of cancer: A population-based cohort study in Denmark","volume":"92","author":"Friis","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0300","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0006-291X(02)00496-5","article-title":"Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis","volume":"294","author":"Fujita","year":"2002","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0305","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1158\/0008-5472.CAN-06-3037","article-title":"The terminology issue for myeloid-derived suppressor cells","volume":"67","author":"Gabrilovich","year":"2007","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0310","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0031-6997(24)01458-3","article-title":"International union of pharmacology. XXIII. The angiotensin II receptors","volume":"52","author":"de Gasparo","year":"2000","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0315","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF00265911","article-title":"Fosinopril pharmacokinetics and pharmacodynamics in chronic ambulatory peritoneal dialysis patients","volume":"41","author":"Gehr","year":"1991","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0320","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.18632\/aging.101249","article-title":"Repurposing ARBs as treatments for breast cancer","volume":"9","author":"George","year":"2017","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0325","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.1111\/febs.12509","article-title":"Unravelling the molecular complexity of GPCR-mediated EGFR transactivation using functional genomics approaches","volume":"280","author":"George","year":"2013","journal-title":"The FEBS Journal"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0330","first-page":"5377","article-title":"A functional siRNA screen identifies genes modulating angiotensin II-mediated EGFR transactivation","volume":"126","author":"George","year":"2013","journal-title":"Journal of Cell Science"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0335","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nrc2945","article-title":"The renin-angiotensin system and cancer: Old dog, new tricks","volume":"10","author":"George","year":"2010","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0340","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1161\/01.RES.0000081593.33848.FC","article-title":"Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: Insights from selective inhibitors","volume":"93","author":"Georgiadis","year":"2003","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0345","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/MPA.0b013e3181c314cd","article-title":"Blocking angiotensin II Type 1 receptor triggers apoptotic cell death in human pancreatic cancer cells","volume":"39","author":"Gong","year":"2010","journal-title":"Pancreas"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0350","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1006\/bbrc.1993.1594","article-title":"Enhanced expression of angiotensin II receptor subtypes and angiotensin converting enzyme in medroxyprogesterone-induced mouse mammary adenocarcinomas","volume":"193","author":"Guerra","year":"1993","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0355","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.cmet.2011.03.001","article-title":"AT1A angiotensin receptors in the renal proximal tubule regulate blood pressure","volume":"13","author":"Gurley","year":"2011","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0360","doi-asserted-by":"crossref","first-page":"49936","DOI":"10.1074\/jbc.M307317200","article-title":"GIT1 mediates Src-dependent activation of phospholipase Cgamma by angiotensin II and epidermal growth factor","volume":"278","author":"Haendeler","year":"2003","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0365","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/1470320310379066","article-title":"The expression of renin-angiotensin system components in the human gastric mucosa","volume":"12","author":"Hallersund","year":"2011","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0370","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nrd.2017.178","article-title":"Trends in GPCR drug discovery: New agents, targets and indications","volume":"16","author":"Hauser","year":"2017","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajps.2019.08.003","article-title":"Tumor microenvironment responsive drug delivery systems","author":"He","year":"2020","journal-title":"Asian Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0380","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0022-3565(25)24476-7","article-title":"Pharmacological effects of GR138950, a novel angiotensin AT1 receptor antagonist","volume":"272","author":"Hilditch","year":"1995","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0385","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/EDE.0000000000001065","article-title":"Renin-angiotensin-aldosterone system-based antihypertensive agents and the risk of colorectal cancer among medicare beneficiaries","volume":"30","author":"Htoo","year":"2019","journal-title":"Epidemiology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0390","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.3892\/mmr.2014.1891","article-title":"Angiotensin II promotes the progression of human gastric cancer","volume":"9","author":"Huang","year":"2014","journal-title":"Molecular Medicine Reports"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0395","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3389\/fsurg.2017.00076","article-title":"Characterization of cancer stem cells in colon adenocarcinoma metastasis to the liver","volume":"4","author":"Humphries","year":"2017","journal-title":"Front Surg"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0400","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1210\/me.2004-0536","article-title":"Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II","volume":"20","author":"Hunyady","year":"2006","journal-title":"Molecular Endocrinology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0405","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1158\/2159-8290.CD-15-1177","article-title":"Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy","volume":"6","author":"Incio","year":"2016","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0410","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/bjc.2013.32","article-title":"Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer","volume":"108","author":"Ino","year":"2013","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0415","doi-asserted-by":"crossref","first-page":"12442","DOI":"10.1073\/pnas.1816410116","article-title":"JAK\/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors","volume":"116","author":"Irey","year":"2019","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0420","doi-asserted-by":"crossref","first-page":"234","DOI":"10.7326\/0003-4819-117-3-234","article-title":"Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology","volume":"117","author":"Israili","year":"1992","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0425","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0430","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1021\/jm00396a033","article-title":"(Phosphinyloxy)acyl amino acid inhibitors of angiotensin converting enzyme (ACE). 1. Discovery of (S)-1-[6-amino-2-[[hydroxy(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]-L -proline a novel orally active inhibitor of ACE","volume":"31","author":"Karanewsky","year":"1988","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0435","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2174\/0929867323666151117122116","article-title":"Leveraging NMR and X-ray data of the free ligands to build better drugs targeting angiotensin II type 1 G-protein coupled receptor","volume":"23","author":"Kellici","year":"2016","journal-title":"Current Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0440","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000337979","article-title":"How does inhibition of the renin-angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy?","volume":"83","author":"Kim","year":"2012","journal-title":"Oncology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0445","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/01.HYP.37.2.587","article-title":"Angiotensin II induces migration and Pyk2\/paxillin phosphorylation of human monocytes","volume":"37","author":"Kintscher","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0450","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/cncr.23215","article-title":"Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion\/deletion polymorphism, and cancer: The Rotterdam study","volume":"112","author":"van der Knaap","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0455","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10585-014-9635-8","article-title":"Blockade of the renin-angiotensin system inhibits growth of colorectal cancer liver metastases in the regenerating liver","volume":"31","author":"Koh","year":"2014","journal-title":"Clinical & Experimental Metastasis"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0460","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00262-008-0618-y","article-title":"A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells","volume":"58","author":"Kong","year":"2009","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0465","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/pros.20486","article-title":"Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer","volume":"67","author":"Kosaka","year":"2007","journal-title":"Prostate"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0470","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1021\/jm021089h","article-title":"Computer-aided selection of potential antihypertensive compounds with dual mechanism of action","volume":"46","author":"Lagunin","year":"2003","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0475","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0140-6736(98)03228-0","article-title":"Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?","volume":"352","author":"Lever","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0480","first-page":"1375","article-title":"The renin-angiotensin system blockers as adjunctive therapy for cancer: A meta-analysis of survival outcome","volume":"21","author":"Li","year":"2017","journal-title":"European Review for Medical and Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0485","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1096\/fj.10-169433","article-title":"Angiotensin-converting enzyme is required for normal myelopoiesis","volume":"25","author":"Lin","year":"2011","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0490","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0031-6997(25)06820-6","article-title":"Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors","volume":"47","author":"Linz","year":"1995","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0495","doi-asserted-by":"crossref","first-page":"5959","DOI":"10.1158\/1078-0432.CCR-17-0256","article-title":"Use of angiotensin system inhibitors is associated with immune activation and longer survival in nonmetastatic pancreatic ductal adenocarcinoma","volume":"23","author":"Liu","year":"2017","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0500","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1126\/science.275.5298.394","article-title":"Linkage of G protein-coupled receptors to the MAPK signaling pathway through PI 3-kinase gamma","volume":"275","author":"Lopez-Ilasaca","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0505","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s12551-019-00555-w","article-title":"Interacting cogs in the machinery of the renin angiotensin system","author":"Lubbe","year":"2019","journal-title":"Biophysical Reviews"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0510","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djt374","article-title":"Angiotensin-converting enzyme inhibitor therapy and colorectal cancer risk","volume":"106","author":"Makar","year":"2014","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0515","doi-asserted-by":"crossref","first-page":"e1342918","DOI":"10.1080\/2162402X.2017.1342918","article-title":"Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer","volume":"6","author":"Malesci","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0520","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/bjc.2016.375","article-title":"The use of drugs acting on the renin-angiotensin system and the incidence of pancreatic cancer","volume":"116","author":"Mandilaras","year":"2017","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0525","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0530","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3109\/00365521.2013.777776","article-title":"The angiotensin II type I receptor blocker olmesartan inhibits the growth of pancreatic cancer by targeting stellate cell activities in mice","volume":"48","author":"Masamune","year":"2013","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0535","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1161\/01.HYP.0000248211.82232.a7","article-title":"Local renin angiotensin expression regulates human mesenchymal stem cell differentiation to adipocytes","volume":"48","author":"Matsushita","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0540","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1517\/13543776.2013.830104","article-title":"AT1 antagonists: A patent review (2008 - 2012)","volume":"23","author":"Mavromoustakos","year":"2013","journal-title":"Expert Opinion on Therapeutic Patents"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0545","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1158\/0008-5472.CAN-06-3614","article-title":"Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2","volume":"67","author":"Menon","year":"2007","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0550","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1358\/mf.1998.20.9.487530","article-title":"Discovery of new angiotensin II receptor antagonists. A review of pharmacological studies","volume":"20","author":"Merlos","year":"1998","journal-title":"Methods and Findings in Experimental and Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0555","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/eci.12557","article-title":"Genetic variants in the renin-angiotensin system predict response to bevacizumab in cancer patients","volume":"45","author":"Moreno-Munoz","year":"2015","journal-title":"European Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0560","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1001\/jamaoncol.2019.0892","article-title":"Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: A phase 2 clinical trial","volume":"5","author":"Murphy","year":"2019","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0565","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1096\/fj.11-191932","article-title":"AT1 receptor blockade delays postlactational mammary gland involution: A novel role for the renin angiotensin system","volume":"26","author":"Nahmod","year":"2012","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0570","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00432-014-1873-2","article-title":"The inhibition of renin-angiotensin system in advanced pancreatic cancer: An exploratory analysis in 349 patients","volume":"141","author":"Nakai","year":"2015","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0575","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/cas.13423","article-title":"Involvement of local renin-angiotensin system in immunosuppression of tumor microenvironment","volume":"109","author":"Nakamura","year":"2018","journal-title":"Cancer Science"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0580","doi-asserted-by":"crossref","first-page":"26C","DOI":"10.1016\/0002-9149(92)90278-7","article-title":"Comparative properties of angiotensin-converting enzyme inhibitors: Relations with inhibition of tissue angiotensin-converting enzyme and potential clinical implications","volume":"69","author":"Nash","year":"1992","journal-title":"The American Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0585","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1124\/mol.65.4.822","article-title":"Scaffolds direct Src-specific signaling in response to angiotensin II: New roles for Cas and GIT1","volume":"65","author":"Natarajan","year":"2004","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0590","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nature01370","article-title":"Crystal structure of the human angiotensin-converting enzyme-lisinopril complex","volume":"421","author":"Natesh","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0595","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/00005344-198505000-00025","article-title":"Biological properties of the angiotensin-converting enzyme inhibitor cilazapril","volume":"7","author":"Natoff","year":"1985","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0600","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1471-2407-10-134","article-title":"Changes in the renin angiotensin system during the development of colorectal cancer liver metastases","volume":"10","author":"Neo","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0605","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1440-1746.2006.04797.x","article-title":"Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases","volume":"22","author":"Neo","year":"2007","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0610","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/jgh.13307","article-title":"Regulation of colorectal cancer cell epithelial to mesenchymal transition by the renin angiotensin system","volume":"31","author":"Nguyen","year":"2016","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0615","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1161\/01.RES.0000125627.77235.0C","article-title":"GIT1 mediates thrombin signaling in endothelial cells: Role in turnover of RhoA-type focal adhesions","volume":"94","author":"van Nieuw Amerongen","year":"2004","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0620","first-page":"355","article-title":"Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities","volume":"22","author":"Noguchi","year":"2009","journal-title":"Oncology Reports"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0625","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-associated macrophages: From mechanisms to therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0630","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/jpet.110.176636","article-title":"In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies","volume":"336","author":"Ojima","year":"2011","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0635","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.canlet.2014.09.019","article-title":"The angiotensin II type 1 receptor blocker candesartan suppresses proliferation and fibrosis in gastric cancer","volume":"355","author":"Okazaki","year":"2014","journal-title":"Cancer Letters"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0640","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3892\/mco.2015.630","article-title":"Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients","volume":"3","author":"Osumi","year":"2015","journal-title":"Molecular and Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0645","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s00384-019-03379-y","article-title":"Angiotensin I-converting enzyme inhibitors\/angiotensin II receptor blockers may reduce tumor recurrence in left-sided and early colorectal cancers","volume":"34","author":"Ozawa","year":"2019","journal-title":"International Journal of Colorectal Disease"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0650","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1158\/1078-0432.CCR-16-1416","article-title":"Signal transduction and activator of transcription-3 (STAT3) in patients with colorectal cancer: Associations with the phenotypic features of the tumor and host","volume":"23","author":"Park","year":"2017","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0655","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3324\/haematol.2009.006965","article-title":"A role for the renin-angiotensin system in hematopoiesis","volume":"94","author":"Park","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0660","doi-asserted-by":"crossref","first-page":"110455","DOI":"10.1016\/j.mce.2019.110455","article-title":"Correlation between renin-angiotensin system (RAS) related genes, type 2 diabetes, and cancer: Insights from metanalysis of transcriptomics data","volume":"493","author":"Pereira","year":"2019","journal-title":"Molecular and Cellular Endocrinology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0665","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1158\/1078-0432.CCR-18-0236","article-title":"Renin-angiotensin system inhibitors to mitigate cancer treatment-related adverse events","volume":"24","author":"Pinter","year":"2018","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0670","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/1078-0432.CCR-18-1543","article-title":"The intersection between tumor angiogenesis and immune suppression","volume":"25","author":"Rahma","year":"2019","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0675","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrd3024","article-title":"Teaching old receptors new tricks: Biasing seven-transmembrane receptors","volume":"9","author":"Rajagopal","year":"2010","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0680","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/ajh.2010.25","article-title":"Increased risk of high-grade hypertension with bevacizumab in cancer patients: A meta-analysis","volume":"23","author":"Ranpura","year":"2010","journal-title":"American Journal of Hypertension"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0685","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/sj.bjp.0703109","article-title":"The effects of Z13752A, a combined ACE\/NEP inhibitor, on responses to coronary artery occlusion; a primary protective role for bradykinin","volume":"129","author":"Rastegar","year":"2000","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0690","doi-asserted-by":"crossref","first-page":"10284","DOI":"10.1073\/pnas.0900351106","article-title":"AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist","volume":"106","author":"Rhodes","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0695","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2147\/IJNRD.S7038","article-title":"Fifteen years of losartan: What have we learned about losartan that can benefit chronic kidney disease patients?","volume":"3","author":"Ripley","year":"2010","journal-title":"International Journal of Nephrology and Renovascular Disease"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0700","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.bmcl.2015.10.084","article-title":"Structural determinants of subtype selectivity and functional activity of angiotensin II receptors","volume":"26","author":"Sallander","year":"2016","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0705","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/annonc\/mdn637","article-title":"Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab","volume":"20","author":"Scartozzi","year":"2009","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0710","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1021\/acs.jcim.6b00524","article-title":"The dynamic nonprime binding of sampatrilat to the C-domain of angiotensin-converting enzyme","volume":"56","author":"Sharma","year":"2016","journal-title":"Journal of Chemical Information and Modeling"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0715","doi-asserted-by":"crossref","first-page":"1 34 31","DOI":"10.1002\/cpbi.46","article-title":"Accessing expert-curated pharmacological data in the IUPHAR\/BPS guide to pharmacology","volume":"61","author":"Sharman","year":"2018","journal-title":"Current Protocols in Bioinformatics"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0720","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/ni.2107","article-title":"The carboxypeptidase ACE shapes the MHC class I peptide repertoire","volume":"12","author":"Shen","year":"2011","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0725","doi-asserted-by":"crossref","DOI":"10.1177\/1470320316656679","article-title":"Renin-angiotensin system blockade for the risk of cancer and death","volume":"17","author":"Shen","year":"2016","journal-title":"Journal of the Renin-Angiotensin-Aldosterone System"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0730","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/labinvest.2014.41","article-title":"Myeloid expression of angiotensin-converting enzyme facilitates myeloid maturation and inhibits the development of myeloid-derived suppressor cells","volume":"94","author":"Shen","year":"2014","journal-title":"Laboratory Investigation"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0735","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.amjcard.2011.03.038","article-title":"Meta-analysis of randomized controlled trials on effect of angiotensin-converting enzyme inhibitors on cancer risk","volume":"108","author":"Sipahi","year":"2011","journal-title":"The American Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0740","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1470-2045(10)70106-6","article-title":"Angiotensin-receptor blockade and risk of cancer: Meta-analysis of randomised controlled trials","volume":"11","author":"Sipahi","year":"2010","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0745","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1084\/jem.103.3.295","article-title":"The preparation and function of the hypertensin-converting enzyme","volume":"103","author":"Skeggs","year":"1956","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0750","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1158\/1078-0432.CCR-04-1946","article-title":"Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination","volume":"11","author":"Suganuma","year":"2005","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0755","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00535-011-0433-7","article-title":"Expression of angiotensin II type 1 and type 2 receptor mRNAs in the gastric mucosa of helicobacter pylori-infected Mongolian gerbils","volume":"46","author":"Sugimoto","year":"2011","journal-title":"Journal of Gastroenterology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0760","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/eurheartj\/ehs181","article-title":"Cancer drugs and the heart: Importance and management","volume":"34","author":"Suter","year":"2013","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0765","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/sj.bjc.6603213","article-title":"Localisation of renin-angiotensin system (RAS) components in breast","volume":"95","author":"Tahmasebi","year":"2006","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0770","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.phrs.2017.06.013","article-title":"Current topics in angiotensin II type 1 receptor research: Focus on inverse agonism, receptor dimerization and biased agonism","volume":"123","author":"Takezako","year":"2017","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0775","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0014-2999(99)00116-8","article-title":"Expression, secretion, and inhibition of angiotensin-converting enzyme in cultured human bronchial epithelial cells","volume":"370","author":"Takimoto","year":"1999","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0780","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1096\/fj.07-8560rev","article-title":"Cancer stem cell: Target for anti-cancer therapy","volume":"21","author":"Tang","year":"2007","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0785","doi-asserted-by":"crossref","first-page":"III136","DOI":"10.1161\/01.HYP.18.5_Suppl.III136","article-title":"Angiotensin II receptor antagonists. From discovery to antihypertensive drugs","volume":"18","author":"Timmermans","year":"1991","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0790","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0165-6147(91)90498-H","article-title":"Nonpeptide angiotensin II receptor antagonists","volume":"12","author":"Timmermans","year":"1991","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0795","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40824-018-0132-z","article-title":"Tumor microenvironment-responsive nanoparticles for cancer theragnostic applications","volume":"22","author":"Uthaman","year":"2018","journal-title":"Biomaterials Research"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0800","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/sj.bjp.0702398","article-title":"Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors","volume":"126","author":"Vanderheyden","year":"1999","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0805","first-page":"489","article-title":"The history of inhibitors of angiotensin converting enzyme","volume":"50","author":"Vane","year":"1999","journal-title":"Journal of Physiology and Pharmacology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0810","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/ERC-11-0335","article-title":"The renin-angiotensin system in the breast and breast cancer","volume":"19","author":"Vinson","year":"2012","journal-title":"Endocrine-Related Cancer"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0815","doi-asserted-by":"crossref","first-page":"930","DOI":"10.3762\/bjoc.14.80","article-title":"On the design principles of peptide-drug conjugates for targeted drug delivery to the malignant tumor site","volume":"14","author":"Vrettos","year":"2018","journal-title":"Beilstein Journal of Organic Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0820","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1002\/jcb.26552","article-title":"Mechanoactivation of the angiotensin II type 1 receptor induces beta-arrestin-biased signaling through Galphai coupling","volume":"119","author":"Wang","year":"2018","journal-title":"Journal of Cellular Biochemistry"},{"issue":"5","key":"10.1016\/j.pharmthera.2020.107527_bb0825","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.ijcard.2012.05.096","article-title":"Long-term use of angiotensin II receptor blockers and risk of cancer: A population-based cohort analysis","volume":"167","author":"Wang","year":"2013","journal-title":"International Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0830","doi-asserted-by":"crossref","first-page":"205S","DOI":"10.1016\/S0895-7061(99)00103-X","article-title":"The renin-angiotensin-aldosterone system: A specific target for hypertension management","volume":"12","author":"Weir","year":"1999","journal-title":"American Journal of Hypertension"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0835","doi-asserted-by":"crossref","first-page":"720","DOI":"10.4161\/cbt.25092","article-title":"The renin angiotensin system regulates Kupffer cells in colorectal liver metastases","volume":"14","author":"Wen","year":"2013","journal-title":"Cancer Biology & Therapy"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0840","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1021\/jm9504722","article-title":"Nonpeptide angiotensin II receptor antagonists: The next generation in antihypertensive therapy","volume":"39","author":"Wexler","year":"1996","journal-title":"Journal of Medicinal Chemistry"},{"issue":"479\u2013490","key":"10.1016\/j.pharmthera.2020.107527_bb0845","article-title":"Distinctive activation mechanism for angiotensin receptor revealed by a synthetic Nanobody","volume":"176","author":"Wingler","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0850","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1002\/cncr.31344","article-title":"Treatment-emergent hypertension and efficacy in the phase 3 study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT)","volume":"124","author":"Wirth","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0855","doi-asserted-by":"crossref","first-page":"D668","DOI":"10.1093\/nar\/gkj067","article-title":"DrugBank: A comprehensive resource for in silico drug discovery and exploration","volume":"34","author":"Wishart","year":"2006","journal-title":"Nucleic Acids Research"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0860","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(08)70003-2","article-title":"Incidence and risk of hypertension with sorafenib in patients with cancer: A systematic review and meta-analysis","volume":"9","author":"Wu","year":"2008","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0865","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature12034","article-title":"Macrophage biology in development, homeostasis and disease","volume":"496","author":"Wynn","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0870","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/med.2610050405","article-title":"Recent developments in the design of angiotensin-converting enzyme inhibitors","volume":"5","author":"Wyvratt","year":"1985","journal-title":"Medicinal Research Reviews"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0875","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/10837450.2016.1265553","article-title":"Losartan loaded liposomes improve the antitumor efficacy of liposomal paclitaxel modified with pH sensitive peptides by inhibition of collagen in breast cancer","volume":"23","author":"Xia","year":"2018","journal-title":"Pharmaceutical Development and Technology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0880","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.tips.2016.09.009","article-title":"Successful strategies to determine high-resolution structures of GPCRs","volume":"37","author":"Xiang","year":"2016","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0885","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1126\/science.7434025","article-title":"pH-sensitive liposomes: possible clinical implications","volume":"210","author":"Yatvin","year":"1980","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0890","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis, and management","volume":"53","author":"Yeh","year":"2009","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0895","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1128\/MCB.24.2.875-885.2004","article-title":"GIT1 functions as a scaffold for MEK1-extracellular signal-regulated kinase 1 and 2 activation by angiotensin II and epidermal growth factor","volume":"24","author":"Yin","year":"2004","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0900","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: A leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0905","first-page":"409","article-title":"Angiotensin-converting enzyme 2-angiotensin (1-7)-Mas axis prevents pancreatic acinar cell inflammatory response via inhibition of the p38 mitogen-activated protein kinase\/nuclear factor-kappaB pathway","volume":"41","author":"Yu","year":"2018","journal-title":"International Journal of Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0910","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1182\/blood-2008-03-144766","article-title":"Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells","volume":"112","author":"Zambidis","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0915","doi-asserted-by":"crossref","first-page":"29127","DOI":"10.1074\/jbc.M115.689000","article-title":"Structural basis for ligand recognition and functional selectivity at angiotensin receptor","volume":"290","author":"Zhang","year":"2015","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0920","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.cell.2015.04.011","article-title":"Structure of the Angiotensin receptor revealed by serial femtosecond crystallography","volume":"161","author":"Zhang","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0925","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13046-019-1127-x","article-title":"Angiotensin II promotes ovarian cancer spheroid formation and metastasis by upregulation of lipid desaturation and suppression of endoplasmic reticulum stress","volume":"38","author":"Zhang","year":"2019","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0930","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1479-5876-8-13","article-title":"The density of macrophages in the invasive front is inversely correlated to liver metastasis in colon cancer","volume":"8","author":"Zhou","year":"2010","journal-title":"Journal of Translational Medicine"},{"key":"10.1016\/j.pharmthera.2020.107527_bb0935","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1039\/c2ib20135f","article-title":"Stimulus-responsive nanopreparations for tumor targeting","volume":"5","author":"Zhu","year":"2013","journal-title":"Integr Biol (Camb)"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725820300553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725820300553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:05:27Z","timestamp":1759010727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725820300553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":186,"alternative-id":["S0163725820300553"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107527","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating the benefits of renin-angiotensin system inhibitors as cancer treatments","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107527","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107527"}}